The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...

Later this month, the US Food and Drug Administration (FDA) will decide whether a new psoriasis drug, Stelara (ustekinumab), can enter the market. The human monoclonal antibody (mAb), developed by ...

--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar ...

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara (Ustekinumab), marking a significant milestone for ...